Agent Service · x402 · early usage

Lyon 2020 HFA-ICOS baseline CV risk before proteasome inhibitors and immunomodulatory d…

by api.magentlab.com · discovered, not yet claimed by its owner · updated 2026-10-12

30d calls3

30d payers1

MethodPOST

Outputjson

Mirrored from Coinbase's public x402 Bazaar. The description is the provider's own text and has not been reviewed here; the payment requirements are copied as published.

What it does

Lyon 2020 HFA-ICOS baseline CV risk before proteasome inhibitors and immunomodulatory drugs for multiple myeloma. Returns risk_level low, medium, high, or very_high plus medium_points and the paper's expert-opinion cardiotoxicity_guide. Age >=75 is High; 65-74 is Medium 1. Caller assigns labs, BMI >30, and high-dose dexamethasone. magent does not examine the patient or read imaging. Not a medical device or treatment order.

Tags: hfa-icos · myeloma · cardio-oncology · hemodynamics · calculator · bazaar

Call contract

Method: POST
Input: HTTP request
Output: json
Last paid call: 2026-10-12

Input example from Bazaar metadata

{
  "items": [
    {
      "age_years": 50,
      "arrhythmia": false,
      "arterial_vascular_disease": false,
      "cardiac_amyloidosis": false,
      "ckd": false,
      "current_or_significant_smoker": false,
      "diabetes": false,
      "elevated_bnp": false,
      "elevated_troponin": false,
      "family_history_thrombophilia": false,
      "heart_failure_or_cardiomyopathy": false,
      "high_dose_dexamethasone": false,
      "hyperlipidemia": false,
      "hypertension": false,
      "left_ventricular_hypertrophy": false,
      "lvef_percent": 60,
      "obesity": false,
      "prior_anthracycline": false,
      "prior_immunomodulatory_drug_cv_toxicity": false,
      "prior_proteasome_inhibitor_cardiotoxicity": false,
      "prior_thoracic_spine_radiotherapy": false,
      "venous_thrombosis": false
    },
    {
      "age_years": 50,
      "arrhythmia": false,
      "arterial_vascular_disease": false,
      "cardiac_amyloidosis": false,
      "ckd": false,
      "current_or_significant_smoker": false,
      "diabetes": false,
      "elevated_bnp": false,
      "elevated_troponin": false,
      "family_history_thrombophilia": false,
      "heart_failure_or_cardiomyopathy": false,
      "high_dose_dexamethasone": false,
      "hyperlipidemia": false,
      "hypertension": false,
      "left_ventricular_hypertrophy": false,
      "lvef_percent": 60,
      "obesity": false,
      "prior_anthracycline": false,
      "prior_immunomodulatory_drug_cv_toxicity": false,
      "prior_proteasome_inhibitor_cardiotoxicity": false,
      "prior_thoracic_spine_radiotherapy": false,
      "venous_thrombosis": false
    }
  ]
}

Output example

{
  "count": 2,
  "items": [
    {
      "age_years": 50,
      "cardiotoxicity_guide": "<2%",
      "citation": {
        "authors": "Lyon AR, Dent S, Stanway S, et al.",
        "doi": "10.1002/ejhf.1920",
        "id": "lyon-2020",
        "pmid": "32458582",
        "source": "Eur J Heart Fail. 2020;22(11):1945-1960",
        "title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society"
      },
      "components": [
        {
          "factor": "heart_failure_or_cardiomyopathy",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "prior_proteasome_inhibitor_cardiotoxicity",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "venous_thrombosis",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "cardiac_amyloidosis",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "arterial_vascular_disease",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "prior_immunomodulatory_drug_cv_toxicity",
          "points": 0,
          "present": false,
          "tier": "high"
        },
        {
          "factor": "elevated_bnp",
          "points": 0,
          "present": false,
          "tier": "high"
        },
        {
          "factor": "prior_anthracycline",
          "points": 0,
          "present": false,
          "tier": "high"
        },
        {
          "factor": "arrhythmia",
          "points": 0,
          "present": false,
          "tier": "medium_2"
        },
        {
          "factor": "elevated_troponin",
          "points": 0,
          "present": false,
          "tier": "medium_2"
        },
        {
          "factor": "left_ventricular_hypertrophy",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "hypertension",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "diabetes",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "hyperlipidemia",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "ckd",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "family_history_thrombophilia",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "prior_thoracic_spine_radiotherapy",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "high_dose_dexamethasone",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "current_or_significant_smoker",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "obesity",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "age_years",
          "points": 0,
          "present": false,
          "tier": "none",
          "value": 50
        },
        {
          "factor": "lvef_percent",
          "points": 0,
          "present": false,
          "tier": "none",
          "value": 60
        }
      ],
      "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
      "formula": "hfa_icos_myeloma",
      "formula_expression": "very_high if any Very high factor (heart_failure_or_cardiomyopathy, prior_proteasome_inhibitor_cardiotoxicity, venous_thrombosis, cardiac_amyloidosis, arterial_vascular_disease); else high if any High factor (prior_immunomodulatory_drug_cv_toxicity, lvef_percent<50, elevated_bnp, age_years>=75, prior_anthracycline) OR medium_points>=5; else medium if medium_points in 2..4; else low (no factors or one Medium 1). medium_points sums Medium 1 (=1: left_ventricular_hypertrophy, age_years 65-74, hypertension, diabetes, hyperlipidemia, ckd, family_history_thrombophilia, prior_thoracic_spine_radiotherapy, high_dose_dexamethasone, current_or_significant_smoker, obesity) and Medium 2 (=2: lvef_percent 50-54, arrhythmia, elevated_troponin) only. Age and LVEF use the highest matching printed band. Lyon 2020 HFA-ICOS multiple-myeloma therapy table. cardiotoxicity_guide is that paper's expert-opinion guide: low <2%, medium 2-9%, high 10-19%, very high >=20%",
      "lvef_percent": 60,
      "medium_points": 0,
      "risk_level": "low"
    },
    {
      "age_years": 50,
      "cardiotoxicity_guide": "<2%",
      "citation": {
        "authors": "Lyon AR, Dent S, Stanway S, et al.",
        "doi": "10.1002/ejhf.1920",
        "id": "lyon-2020",
        "pmid": "32458582",
        "source": "Eur J Heart Fail. 2020;22(11):1945-1960",
        "title": "Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society"
      },
      "components": [
        {
          "factor": "heart_failure_or_cardiomyopathy",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "prior_proteasome_inhibitor_cardiotoxicity",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "venous_thrombosis",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "cardiac_amyloidosis",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "arterial_vascular_disease",
          "points": 0,
          "present": false,
          "tier": "very_high"
        },
        {
          "factor": "prior_immunomodulatory_drug_cv_toxicity",
          "points": 0,
          "present": false,
          "tier": "high"
        },
        {
          "factor": "elevated_bnp",
          "points": 0,
          "present": false,
          "tier": "high"
        },
        {
          "factor": "prior_anthracycline",
          "points": 0,
          "present": false,
          "tier": "high"
        },
        {
          "factor": "arrhythmia",
          "points": 0,
          "present": false,
          "tier": "medium_2"
        },
        {
          "factor": "elevated_troponin",
          "points": 0,
          "present": false,
          "tier": "medium_2"
        },
        {
          "factor": "left_ventricular_hypertrophy",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "hypertension",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "diabetes",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "hyperlipidemia",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "ckd",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "family_history_thrombophilia",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "prior_thoracic_spine_radiotherapy",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "high_dose_dexamethasone",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "current_or_significant_smoker",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "obesity",
          "points": 0,
          "present": false,
          "tier": "medium_1"
        },
        {
          "factor": "age_years",
          "points": 0,
          "present": false,
          "tier": "none",
          "value": 50
        },
        {
          "factor": "lvef_percent",
          "points": 0,
          "present": false,
          "tier": "none",
          "value": 60
        }
      ],
      "disclaimer": "Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.",
      "formula": "hfa_icos_myeloma",
      "formula_expression": "very_high if any Very high factor (heart_failure_or_cardiomyopathy, prior_proteasome_inhibitor_cardiotoxicity, venous_thrombosis, cardiac_amyloidosis, arterial_vascular_disease); else high if any High factor (prior_immunomodulatory_drug_cv_toxicity, lvef_percent<50, elevated_bnp, age_years>=75, prior_anthracycline) OR medium_points>=5; else medium if medium_points in 2..4; else low (no factors or one Medium 1). medium_points sums Medium 1 (=1: left_ventricular_hypertrophy, age_years 65-74, hypertension, diabetes, hyperlipidemia, ckd, family_history_thrombophilia, prior_thoracic_spine_radiotherapy, high_dose_dexamethasone, current_or_significant_smoker, obesity) and Medium 2 (=2: lvef_percent 50-54, arrhythmia, elevated_troponin) only. Age and LVEF use the highest matching printed band. Lyon 2020 HFA-ICOS multiple-myeloma therapy table. cardiotoxicity_guide is that paper's expert-opinion guide: low <2%, medium 2-9%, high 10-19%, very high >=20%",
      "lvef_percent": 60,
      "medium_points": 0,
      "risk_level": "low"
    }
  ],
  "path": "/api/calc/hfa_icos_myeloma"
}

Use with an agent

Discover. Agents find this listing with GET https://bazaar.saylorinnovations.com/discovery/search?query=…, the MCP tool search_resources, or /discovery/resources.
Inspect. Fetch /resources/39587.json for the price and payment options.
Pay. Call GET https://api.magentlab.com/api/calc/hfa_icos_myeloma. The provider answers 402 with its payment requirements. An x402 client signs one of the options below and retries with PAYMENT-SIGNATURE.
Execute. The provider returns 200 with the data. Agent Bazaar is not in the request path and never sees your payment.

For humans

You don't need an account or an API key; you need a wallet holding a small amount of USDC on Base, and an x402-capable client (see the examples below). Call the endpoint unpaid first to see exactly what it asks for.

Pricing & payment

Price: $0.005 / request
Protocol: x402 v2
Auth: No account or API key. Pay per request.
Networks: Base
Demand: 3 calls · 1 unique payers in 30d (public x402 Bazaar data)

x402 payment requirements

Scheme	Network	Asset	Amount	Pay to	Timeout
exact	Base eip155:8453	USDC	$0.005	0x836Be278f1739fB4308091cD1852F7971Bc19Ee2	600s

accepts[] (raw JSON)

[
  {
    "scheme": "exact",
    "network": "eip155:8453",
    "payTo": "0x836Be278f1739fB4308091cD1852F7971Bc19Ee2",
    "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
    "amount": "5000",
    "amountUsd": 0.005,
    "maxTimeoutSeconds": 600
  }
]

Schemas

Output schema (JSON Schema)

{
  "properties": {
    "example": {
      "type": "object"
    },
    "type": {
      "type": "string"
    }
  },
  "required": [
    "type"
  ],
  "type": "object"
}

Example shape — generated from the schema, not a captured live response

{
  "example": {},
  "type": "string"
}

Examples

curl

curl "https://api.magentlab.com/api/calc/hfa_icos_myeloma"
# -> 402 Payment Required, accepts[] lists how to pay
# retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paid

JavaScript

const res = await fetch("https://api.magentlab.com/api/calc/hfa_icos_myeloma");
if (res.status === 402) {
  const { accepts } = await res.json();
  // pay one of accepts[] via an x402 client, then retry with the payment header
}

Python

import httpx
res = httpx.get("https://api.magentlab.com/api/calc/hfa_icos_myeloma")
if res.status_code == 402:
    accepts = res.json()["accepts"]
    # pay one of accepts[] via an x402 client, then retry with the payment header

Details

Provider: api.magentlab.com
Endpoint: https://api.magentlab.com/api/calc/hfa_icos_myeloma
Machine-readable: /resources/39587.json